

Haematologica
HAEMATOL/2018/195834
Version 4

Advances in risk assessment and prophylaxis for central nervous
system relapse in diffuse large B-cell lymphoma

David Qualls and Jeremy S. Abramson

Disclosures: Dr. Qualls has nothing to disclose Dr. Abramson discloses consulting for Abbvie, Amgen, Bayer, Celgene, Gilead, Janssen, Juno therapeutics, Karyopharm, Kite pharma, Merck, Novartis, Seattle Genetics, Verastem

Contributions: DQ and JA wrote and edited the manuscript